🗂️

Archived grant — no longer open

This grant has closed and is kept as a historical reference. Browse current grants for active opportunities.

grant

Administration of intratumoral immunocytokine to activate immune rejection of spontaneous canine melanoma

Organization WM S. MIDDLETON MEMORIAL VETERANS HOSPLocation MADISON, UNITED STATESPosted 1 Sept 2019Deadline 31 Aug 2025 ⚠️
VANIHUS FederalResearch GrantFY2026AgeAnimal ModelAnimal Models and Related StudiesAnimalsAntigensAntitumor ResponseAutologousBiologicalBiological MarkersBiopsyBlood SampleBlood VesselsBlood specimenBrainBrain Nervous SystemCancer PatientCancersCanine SpeciesCanis familiarisCell Surface AntigensClinicalClinical EvaluationClinical TestingClinical Treatment MoabClinical assessmentsClonalityCo-StimulatorCombination immunotherapyCombined Modality TherapyCompanionsCostimulatorDataDiseaseDisorderDistantDogsDogs MammalsDoseElementsEncephalonEnvironmental ExposureEpidermal Thymocyte Activating FactorExposure to ultraviolet radiationFutureGenderGoalsHealthHistologicHistologicallyHumanIL-2IL2 ProteinImageImmuneImmune MonitoringImmune ToleranceImmune mediated therapyImmune systemImmunesImmunochemical ImmunologicImmunologicImmunologic MonitoringImmunologic ToleranceImmunologicalImmunological MonitoringImmunological Surface MarkersImmunologicallyImmunologically Directed TherapyImmunologicsImmunomonitoringImmunosuppressionImmunosuppression EffectImmunosuppressive EffectImmunotherapyIndividualInjectionsInterleukin 2Interleukin 2 PrecursorInterleukin IIInterleukin-2Interleukine 2Interleukine 2 PrecursorInterleukine IIKidneyKidney Urinary SystemKnowledgeLearningLesionLiverLungLung Respiratory SystemLymphocyte Mitogenic FactorMalignant MelanomaMalignant NeoplasmsMalignant TumorMaximal Tolerated DoseMaximally Tolerated DoseMaximum Tolerated DoseMeasurementMediatingMelanomaMelanoma MetastasisMelanoma TumorMelanoma patientMetastasisMetastasizeMetastatic LesionMetastatic MassMetastatic MelanomaMetastatic NeoplasmMetastatic TumorMiceMice MammalsMitogenic FactorModelingModern ManMonitorMonoclonal AntibodiesMultimodal TherapyMultimodal TreatmentMurineMusMutateNeoplasm MetastasisOccupationalPD-1 antibodyPD1 antibodyPatientsPersonsPre-Clinical ModelPreclinical ModelsPrevalenceRadiation therapyRadiotherapeuticsRadiotherapyRecombinant Fusion ProteinsRegimenRiskSafetySamplingSecondary NeoplasmSecondary TumorSiteSurface AntigensT cell growth factorT cell infiltrationT cell responseT-Cell Growth FactorT-Cell Stimulating FactorT-CellsT-LymphocyteT-cell receptor repertoireTCR repertoireTestingThymocyte Stimulating FactorToxic effectToxicitiesTranslationsTumor growth in melanomaUV Radiation ExposureUV exposureUltraviolet Radiation Related ExposureUltraviolet radiation exposureVaccinesVeteransVeterans HospitalsWorkaPD-1aPD1agesanti programmed cell death 1anti-PD-1anti-PD-1 Abanti-PD-1 antibodiesanti-PD-1 monoclonal antibodiesanti-PD1anti-PD1 Abanti-PD1 antibodiesanti-PD1 monoclonal antibodiesanti-cancer immunotherapyanti-cancer therapeuticanti-programmed cell death protein 1anti-programmed cell death protein 1 antibodiesanti-programmed death-1 antibodyanti-tumor effectanti-tumor responseantiPD-1anticancer immunotherapyantitumor effectbio-markersbiologicbiologic markerbiomarkerbiomarker identificationcancer diagnosiscancer immunotherapycancer metastasiscandidate biomarkercandidate markercaninecartilage link proteincheck point blockadecheckpoint blockadeclinical investigationclinical relevanceclinical testclinically relevantcombination therapycombinatorial immunotherapycombined modality treatmentcombined treatmentcompanion dogdesigndesigningdisialogangliosidesdomestic dogdraining lymph nodedual immunotherapyeffective therapyeffective treatmentexposure to environmental agentsexposure to environmental factorsexposure to environmental stimuliexposure to environmental substanceshepatic body systemhepatic organ systemidentification of biomarkersidentification of new biomarkersimagingimmune check point blockadeimmune checkpoint blockadeimmune suppressionimmune suppressive activityimmune suppressive functionimmune system toleranceimmune therapeutic approachimmune therapeutic interventionsimmune therapeutic regimensimmune therapeutic strategyimmune therapyimmune unresponsivenessimmune-based cancer therapiesimmune-based therapiesimmune-based treatmentsimmuno therapyimmunogenimmunogenicityimmunological paralysisimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseimmunotherapy for cancerimmunotherapy of cancerin situ anti-tumor vaccinein situ antitumor vaccinein situ cancer vaccinein situ tumor vaccinein vivoindividual responseindividualized responselink proteinlymph channellymph vessellymphatic channellymphatic vesselmAbsmalignancymarker identificationmelanoma cancer modelmelanoma modelmelanoma tumor modelmilitary veteranmodel of animalmonoclonal Absmonosialogangliosidesmouse modelmulti-modal therapymulti-modal treatmentmurine modelneo-antigenneo-epitopesneoantigensneoepitopesneoplasm/cancernovelpatients suffering from melanomapatients with melanomaperipheral bloodpersonalization of treatmentpersonalized medicinepersonalized therapypersonalized treatmentpre-clinicalpreclinicalradiation treatmentregional lymph noderenalresearch clinical testingresponseresponse biomarkerresponse markersresponse to therapyresponse to treatmentsialogangliosidesstandard of caretherapeutic responsetherapy responsethymus derived lymphocytetranslationtreatment responsetreatment responsivenesstreatment with radiationtumortumor cell metastasisultraviolet exposureultraviolet light exposurevascularveteran populationvirtualαPD-1αPD1

Applications closed.

Description preview

Malignant melanoma is a serious health issue for Veterans, and metastatic melanoma is usually incurable if it
metastasizes to distant sites. Exciting and impressive data with immune checkpoint blockade demonstrate the
ability of the immune system to produce durable responses in some metastatic melanoma patients and have
changed the standard of…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →

Explore more

📍 More grants in UNITED STATES🏷 More VA opportunities🏷 More NIH opportunities🏷 More US Federal opportunities🏢 All nih_reporter opportunities